Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16244419 | 0.84 | ALOX15 (0.39) | EGFRTSHR | |
| SCHEMBL14991449 | 0.79 | EGFR (0.37) | EGFRTSHR | |
| SCHEMBL19221404 | 0.78 | EGFR (0.36) | EGFR | |
| SCHEMBL7336059 | 0.76 | MAPT (0.39) | EGFRTSHR | |
| SCHEMBL14716655 | 0.76 | EGFR (0.36) | EGFR | |
| SCHEMBL29210356 | 0.74 | TSHR (0.58) | TSHR | |
| SCHEMBL11750414 | 0.74 | TSHR (0.39) | EGFRTSHR | |
| SCHEMBL25899867 | 0.74 | EGFR (0.35) | EGFR | |
| SCHEMBL11750771 | 0.74 | TSHR (0.39) | EGFRTSHR | |
| Lithium Ion SCHEMBL14716654 | 0.74 | EGFR (0.35) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10478492-B2 | Modifications of therapeutic agents for enhanced delivery to target sites | CLARIA PARTIKULA LLC (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180028647-A1 | MODIFICATIONS OF THERAPEUTIC AGENTS FOR ENHANCED DELIVERY TO TARGET SITES | CLARIA ODIN LLC | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028647-A1 | MODIFICATIONS OF THERAPEUTIC AGENTS FOR ENHANCED DELIVERY TO TARGET SITES | PDK1, PC, PDK2 | EGFR 583/4885TSHR 2436/4885 |
| US-10478492-B2 | Modifications of therapeutic agents for enhanced delivery to target sites | PDK1, PC, PDK2 | EGFR 583/4885TSHR 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.